Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of High Infusion Rates of Octagam 10% in Primary Immunodeficiency
NCT01313507Phase 3Completed
- Sponsor
- Octapharma
- Start
- May 2011
- Primary completion
- Sep 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in primary immunodeficiency disease (PID), sponsored by Octapharma. Started May 2011; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT01313507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313507.